ASCO 2024 – J&J shifts to a new radiopharma dosing strategy
The group is keeping faith with the novel target KLK2.
ASCO 2024 – Blenrep “should return” to the US
Dreamm-8 is heralded as marking doctors’ ability to deal better with Blenrep’s toxicities.
ASCO 2024 – Enhertu nears its “ultralow” dream
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
ASCO 2024 – some Adriatic fears allayed
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
ASCO 2024 – Laura’s crossover conundrum
Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.
